AiM Covid Self Monitoring

Efficacy of AiM Covid Self Monitoring in Detecting Infection of COVID-19

The objectives of this study are to test the level of accuracy of the prediction models that could be used as a 'digital test' to evaluate whether an individual is infected with COVID-19, based on their symptoms reported in the "AiM COVID-19" app

Study Overview

• Status: Completed
• Conditions: Covid19
• Intervention / Treatment: Other: Other

• Study Type: Observational
• Enrollment (Actual): 1000

Contacts and Locations

Study Locations

• India
  • Maharashtra
    • Mumbai, Maharashtra, India
      • Mothers Touch Foundation
  • Rajasthan
    • Jaipur, Rajasthan, India
      • NMP Medical Research Institite

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Anyone worried about heath status relating with infection of COVID-19

Description

Inclusion Criteria:

• Participants resident in India
• Voluntary completion of the self-test and evaluation.

Exclusion Criteria:

• People can not use mobile app
• Below 18 years old

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
AiM Covid; Self Monitoring of symptoms in AiM Covid App	Other: Other; No Intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Fever	Self reported body temperature (Degrees Celsius)	1 day

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Shortness of Breath	Self reported shortness of breath symptom (tick box)	1 day
Cough	Self reported cough symptom (tick box)	1 day
Sore Throat	Self reported soar throat symptom (tick box)	1 day
Headache	Self reported headache symptom (tick box)	1 day
Muscle/ Joint Pain	Self reported muscle/ joint pain symptom (tick box)	1 day
Diarrhoea	Self reported diarrhoea symptom (tick box)	1 day
Vomiting/ Nausea	Self reported vomiting/ nausea symptom (tick box)	1 day
Runny Nose	Self reported runny nose symptom (tick box)	1 day
Loss of Smell/Taste	Self reported loss of smell/ taste symptom (tick box)	1 day
Other symptoms	Self reported other symptoms (tick box)	1 day

Collaborators and Investigators

• Sponsor: Aarogyam UK
• Collaborators: University of Warwick; NMP Medical Research Institute; Mothers Touch Foundation
• Investigators: Principal Investigator: Vishwes Kulkarni, University of Warwick

Study record dates

Study Major Dates

• Study Start (Actual): April 12, 2020
• Primary Completion (Actual): May 18, 2020
• Study Completion (Actual): May 28, 2020

Study Registration Dates

• First Submitted: June 9, 2020
• First Submitted That Met QC Criteria: June 9, 2020
• First Posted (Actual): June 11, 2020

Study Record Updates

• Last Update Posted (Actual): June 11, 2020
• Last Update Submitted That Met QC Criteria: June 9, 2020
• Last Verified: June 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: Au015

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No